학술논문
Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000
Document Type
article
Author
Takashi Taida; Yuki Ohta; Jun Kato; Sadahisa Ogasawara; Yuhei Ohyama; Yukiyo Mamiya; Hayato Nakazawa; Ryosuke Horio; Chihiro Goto; Satsuki Takahashi; Akane Kurosugi; Michiko Sonoda; Wataru Shiratori; Tatsuya Kaneko; Yuya Yokoyama; Naoki Akizue; Yotaro Iino; Junichiro Kumagai; Hideaki Ishigami; Hirotaka Koseki; Kenichiro Okimoto; Keiko Saito; Masaya Saito; Tomoaki Matsumura; Tomoo Nakagawa; Shinichiro Okabe; Hirofumi Saito; Kazuki Kato; Hirotsugu Uehara; Hideaki Mizumoto; Yoshihiro Koma; Ryosaku Azemoto; Kenji Ito; Hidehiro Kamezaki; Yoshifumi Mandai; Yoshio Masuya; Yoshihiro Fukuda; Yoshio Kitsukawa; Haruhisa Shimura; Toshio Tsuyuguchi; Naoya Kato
Source
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Subject
Language
English
ISSN
2045-2322
Abstract
Abstract Many molecular targeted agents, including biologics, have emerged for inflammatory bowel diseases (IBD), but their high prices have prevented their widespread use. This study aimed to reveal the changes in patient characteristics and the therapeutic strategies of IBD before and after the implementation of biologics in Japan, where the unique health insurance system allows patients with IBD and physicians to select drugs with minimum patient expenses. The analysis was performed using a prospective cohort, including IBD expert and nonexpert hospitals in Japan. In this study, patients were classified into two groups according to the year of diagnosis based on infliximab implementation as the prebiologic and biologic era groups. The characteristics of therapeutic strategies in both groups were evaluated using association analysis. This study analyzed 542 ulcerative colitis (UC) and 186 Crohn’s disease (CD). The biologic era included 53.3% of patients with UC and 76.2% with CD, respectively. The age of UC (33.9 years vs. 38.8 years, P